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Extracellular vesicles, and in particular, the sub-class exosomes, are rapidly emerging as a 19 
novel therapeutic platform. However, currently very few clinical validation studies and no 20 
clearly defined manufacturing process exist. As exosomes progress towards the clinic for 21 
treatment of a vast array of diseases, it is important to define the engineering basis for their 22 
manufacture early in the development cycle to ensure they can be produced cost-effectively 23 
at the appropriate scale. We hypothesize that transitioning to defined manufacturing 24 
platforms will increase consistency of the exosome product and improve their clinical 25 
advancement as a new therapeutic tool. We present manufacturing technologies and 26 
strategies that are being implemented and consider their application for the transition from 27 
bench-scale to clinical production of exosomes. 28 
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Extracellular Vesicles: Biogenesis, Inherited Function and Clinical Relevance  29 
Living cells release vesicles into the local environment and research into the potential 30 
therapeutic benefits of different extracellular vesicle (EV) types has led to exciting discoveries 31 
leading to the possibility of adopting EVs as new candidate therapeutic agents.  32 
EV biogenesis occurs via several mechanisms [1]–[5] resulting in vesicles of different size and 33 
architecture. Broadly speaking, there are three main sub-classes of EVs: microvesicles that 34 
are shed directly from the cell membrane and have a size range of 50-1000nm diameter; 35 
apoptotic blebs derived from dying cells, typically 50-4000nm; and exosomes which are 36 
smaller, with an approximate size range of 20-150nm -- although this range is variable 37 
between research groups [5]–[11]. Exosomes are released from multivesicular bodies (MVBs) 38 
rather than directly from the cell membrane via exocytosis -- a feature which distinguishes 39 
these vesicles from other sub-classes [4], [12], [13]. During this process, exosomes are loaded 40 
with various types of bioactive cargo (Figure 1), comprised of protein and RNA molecules 41 
(including messenger RNAs (mRNA) and microRNAs (miRNA) [5]. 42 
A growing body of research into stem cell therapy has revealed that the mode of action 43 
underlying the therapeutic effects of stem cells occurs largely via paracrine signaling [14]–44 
[17]. This understanding has evolved based on the fact that implanted cells do not often 45 
engraft or persist long-term, but rather, generate paracrine effects, which can be mediated 46 
by exosomes transmitting information into resident tissue cells. Indeed, post-injury tissue 47 
regeneration studies have revealed that the regenerative effect of exosomes can be as potent 48 
as that of parent cells in promoting regeneration and functional recovery in experimental 49 
models including stroke [14], traumatic brain injury [15], pulmonary hypertension [16] and 50 
wound healing [17]. 51 
In this way, exosomes are effective communication vehicles that transfer bioactive proteins 52 
and genetic material between cells [18]–[20]. The exosome cargo ensures continued 53 
therapeutic effects long after the implanted cells have perished or migrated away from the 54 





The Biologic and Clinical Basis for EVs as Therapeutic Agents 58 
There is widespread consensus that EVs have a biologic signature that reflects the phenotype 59 
of the cells that produced them [21]. For this reason, the potential applications of EVs in a 60 
clinical context are diverse.  61 
On the one hand, EVs have been proposed as diagnostic biomarkers of disease in cancers as 62 
diverse as ovarian cancer [22], [23], glioblastoma [19], melanoma [24] prostate cancer [25]  63 
and colon cancer  [26], based on unique miRNA profiles and other cargo that is transmitted 64 
with pathological effect. Similarly, they might be used as biomarkers of infectious disease, 65 
based on that fact that they transmit infection-specific elements. For example, exosomes 66 
isolated from Huh 7.5 cell lines infected with Hepatitis C virus have been reported to infect 67 
primary human hepatocytes [27]. 68 
On the other hand, they can also act as potent mediators of cell signaling, which might be 69 
exploited for medicinal purposes. For example, they are able to transfer RNA and protein 70 
instructional cues from producing cells to other cells in the surrounding milieu [18]. This can 71 
have striking effects, as evidenced from experiments where EVs derived from mouse 72 
embryonic stem cells promoted the survival and expansion of mouse hematopoietic stem 73 
cells in vitro, while also upregulating transcription factors associated with pluripotency in 74 
recipient cells [28]. These findings also suggest that exosomes can be potentially harvested, 75 
purified and potentially used as a biologic to control undesired or pathophysiologic 76 
conditions.  77 
This concept is further supported by in vivo studies. For example, exosomes isolated from 78 
indoleamine 2,3-dioxygenase-positive dendritic cells were found to reduce inflammation in a 79 
mouse model of collagen-induced arthritis [29]. The exosomes, isolated using differential 80 
centrifugation, were <100 nm in size (as assessed from electron microscopy) and expressed 81 
typical exosome markers such as CD81, hsc70 and CD80/86, as shown from Western blotting 82 
and Fluorescence-Activated Cell Sorting (FACS) [29].   83 
Other studies have suggested the potential therapeutic application of exosomes in 84 
cardiovascular disease. For instance, two mouse models of cardiac ischemia/reperfusion 85 
injury (in vivo myocardial infarction and ex vivo Langendorff heart) showed that mesenchymal 86 
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stem cell (MSC)-derived exosomes with a size range of 55–65 nm resulted in a 50% reduction 87 
in infarct size, measured as a percentage of the area at risk, when compared to saline controls 88 
[30].  89 
Recently, EVs were found to promote regeneration after stroke injury in both rat [31] and 90 
mouse [14]. In both models, functional recovery was accompanied by cellular and molecular 91 
evidence of neurogenic and angiogenic regeneration. For example, in the mouse model, MSC-92 
derived EVs of undisclosed size were able to support neuronal survival and neurogenesis in 93 
the post-ischemic tissue to a level similar to that of parent MSCs, as measured from co-94 
expression of markers of cell division and identity [14]. This also translated into improved 95 
motor coordination function in the animals.  96 
With growing evidence that EVs such as exosomes might stimulate regeneration or modulate 97 
pathologic conditions, there is a good rationale for pursuing the development of EVs as new 98 
potential therapeutic agents.  99 
However, exosomes are yet to be clinically validated as only a handful of studies have been 100 
undertaken, or are currently ongoing. These include the use of autologous, modified 101 
dendritic-derived EVs for maintenance immunotherapy [32], [33], allogeneic MSC-derived EVs 102 
for the treatment of chronic kidney disease [34], type I diabetes mellitus (clinical trial 103 
NCT02138331), acute ischemic stroke (clinical trial NCT03384433), and autologous plasma-104 
derived EVs for cutaneous wound repair (clinical trial NCT02565264). In addition, a single 105 
patient with graft versus host disease was treated with allogeneic MSC-EVs [35]. Existing data 106 
from these trials indicate that exosomes may have potential therapeutic value in a number of 107 
indications without having necessarily met the primary trial endpoint. However, it should be 108 
noted that across these small number of studies, a variety of purification methods have been 109 
utilized, including filtration, ultracentrifugation and PEG precipitation, which may well impact 110 
the consistency of the final products. For example, reported that across 32 preparations of 111 
exosomes generated for clinical use and purified using ultrafiltration/diafiltration followed 112 
ultracentrifugation, final exosomal protein quantity ranged from 99 – 26,648 g [33]. 113 
Therefore, we hypothesise that only when manufacturing challenges have been addressed 114 
will it be possible to create greater consistency in the final product to advance these therapies 115 
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into the clinic; the sooner these manufacturing challenges are addressed in the product 116 
development cycle, the faster patients may have access to them. 117 
Broadly, these challenges may include i) a detailed characterization of exosome material to 118 
define target product attributes, including discrimination of non-exosomal artifacts and even 119 
exosome sub-populations; ii) scalable cell culture methods for upstream production of 120 
exosomes; and iii) scalable downstream processing for isolation and purification of exosomes. 121 
 122 
Limitations of Cell Culture:  123 
Exosomes are secreted products of cells; thus their manufacture is dependent on the ability 124 
to produce large quantities of cells in ways that do not alter the cell phenotype. Presumably, 125 
cellular changes due to transitioning from conventional bench-scale cell culture using planar 126 
t-flasks to scalable cell culture platforms might likely alter the composition and function of its 127 
exosomes. Large scale stem cell cultures are still a rate-limiting step for delivering stable and 128 
potent products at phase III and market scale due to high development costs and regulatory 129 
and market uncertainty [36]–[41]. Accordingly, the opportunities for producing large 130 
quantities of stem cell-conditioned medium with which to undertake meaningful scale-up 131 
studies on exosome production are limited [42]. This was evident in the worldwide survey 132 
conducted by Gardiner et al. who show that that 77% of respondents used less than 100mL 133 
of starting material despite 83% of researchers using material generated from cell culture 134 
[43].   135 
The research efforts into scaling up cell culture have focused on technologies to maximize 136 
surface area, such as micro-carriers in stirred bioreactors [44], [45] or hollow-fiber 137 
bioreactors [46], which offer greater process control (Figure 3). The main technical limitation 138 
of these technologies, is the need for control of environmental parameters within the reactors 139 
such that the phenotype of the cell (and derivative exosomes) does not change. When moving 140 
from static, planar cultures to dynamic, well-mixed 3D environments with high force 141 
generation (impellers, cavitation of bubbles from oxygen sparging), the risk of phenotypic 142 
alterations at the cellular level due to shear stress is still an issue that needs to be addressed. 143 
For example, T-cell expansion was reduced when agitated at 180 rpm in bioreactors as a 144 
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consequence of rapid downregulation of interleukin-2 receptor [47]. In the case of MSCs, a 145 
prominent candidate cell type for the production of candidate therapeutic exosomes, shear 146 
stress  was found to induce mechanotransduction pathways involving p38 mitogen-activated 147 
protein kinase and extracellular signal-related kinase, that could lead to osteogenic 148 
differentiation [48]; these outcomes would likely change the exosome product, although this 149 
remains to be directly demonstrated. 150 
At the extremes of an operating window, limiting cell death in these high-shear systems to 151 
minimize impurities derived from apoptotic blebs is of paramount importance. Apoptotic 152 
blebs overlap in size and might increase heterogeneity, as well as reduce the potency of 153 
exosome products [49], [50]; an example of this heterogeneity was shown in a study 154 
conducted on between dendritic cell derived apoptotic vesicles and exosomes, that exosomal 155 
fractions had their own unique molecular composition and properties [51]. They might even 156 
induce undesirable cell signaling events, although this warrants further investigation.  157 
As cells produce and secrete exosomes naturally, perfusion-based cultures (for example using 158 
hollow-fiber and packed bed technologies), should also be considered with the aim of 159 
providing adequate mass transfer in the cell culture. A key practical benefit in this approach 160 
is that these reactor systems can be designed and optimized to retain the exosome product 161 
within the culture compartment to yield a more concentrated conditioned medium, thereby 162 
reducing liquid handling requirements further downstream [52]. Here, there have been 163 
developments using novel flask “bioreactors” such as the Integra CELLine systems [53] which 164 
can concentrate exosomes within a membrane compartment which allows for media 165 
component transfer over a prolonged period of time in culture. A limitation is that these flasks 166 
are still limited to being a scale-out approach and the harvest window is time-limited because 167 
cells can undergo contact inhibition and changes in behaviour at high densities, as revealed 168 
in one particular study where that mouse adipose mesenchymal stem cells plated at high 169 
seeding densities (90%) had altered gene expression within 48 hours [54]. However, if 170 
exosomes are harvested before cultures are over-confluent, they might better conserve 171 
product parameters as they provide a similar mode of culture to planar t-flasks, unlike 172 
dynamic bioreactor systems. 173 
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An additional limitation for scaling up cell cultures to produce exosomes is the continued 174 
heavy reliance on animal serum for optimal cell growth. For example, fetal bovine serum (FBS) 175 
is high in endogenous exosomes [55], and if not removed prior to cell culture, these process-176 
related impurities may make their way into the final drug product, which from a regulatory 177 
standpoint for an injectable, is completely unfavorable. Therefore, xeno-free culture media 178 
components are desired, provided they conserve comparable cell characteristics and 179 
exosome product attributes that are expected to be therapeutic. However, this task is not 180 
trivial. At the very least, exosome-depleted FBS should be characterized as a means of 181 
confirming it is truly the stem cell-derived exosomes that confer the functional properties 182 
ascribed to them.   183 
A recent study on exosome production further highlighted the importance of culture 184 
reagents, notably FBS-containing versus serum-free medium. Specifically, both human and 185 
mouse neuroblastoma lines showed that switching from FBS-containing to serum-free 186 
medium left the resultant exosomes from both species unchanged in terms of biophysical and 187 
size characteristics [35]. However, the number of exosomes generated was increased when 188 
using serum-free reagents. While this may appear promising, further proteomic analysis 189 
showed that the serum-free exosomes contained reactive oxygen species and stress related 190 
proteins, whereas exosomes derived from cells cultured in serum-containing medium 191 
promoted higher levels of production of RNA processing proteins. As a result, the switch from 192 
FBS-containing medium to serum-free appeared to cause a shift in exosomal biology, 193 
presumably reflecting stress-induced phenotypic changes in culture [56].  These data 194 
illustrate how important culture conditions are in the manufacturing process, as changes can 195 
significantly modify the exosome product profile, which might in turn result in failure at the 196 
regulatory/clinical levels. 197 
One significant advantage of generating exosomes as products, rather than using parent cells 198 
is that the exosome-rich conditioned medium can be separated with ease from producer cells, 199 
where the cells are adherent. This overcomes one of the main challenges for adherent cell 200 
products, which need to be enzymatically detached from microcarriers, where harvesting and 201 
recovery are achieved with limited efficiency due to the need to conserve the cells for 202 
application whilst ensuring damage from extended enzyme exposure is limited [57]. 203 
Furthermore, with the advances in cell engineering and medical research, one may hopefully 204 
8 
 
expect more economically viable, exosome dedicated cell-lines which might provide high 205 
expression of tailor-made exosomes in the future. 206 
 207 
Downstream Processing for Efficient Purification 208 
There are also significant downstream processing challenges to manufacturing exosomes. 209 
First, methods currently employed to enrich exosomes from cell culture media are 210 
grandfathered in from the early viral purification industry which operate via physical 211 
discrimination of target material from impurities. Here, four main isolation methods are used: 212 
size exclusion (based on typical exosomal diameters); sedimentation force or flotation 213 
density; [non-specific] precipitation based methods; and affinity based capture. 214 
The most commonly used method has historically been ultracentrifugation [43], [58]. Two 215 
main variations of ultracentrifugation are used. The first uses a combination of different 216 
centrifugal forces to reduce contamination by cell debris/fragments (3000-10,000g), then 217 
organelles and non-exosomal vesicles (10,000-20,000g), before a final pellet of the exosomes 218 
is produced (100,000-120,000g). The second discriminates exosomes from other vesicles via 219 
flotation using density gradients made from deuterium oxide (D2O)/sucrose cushions or 220 
commercially available reagents such as iodixanol [59]. In spite of these protocols however, 221 
co-isolation of non-exosomal vesicles and other particulate debris that share similar size and 222 
density is still observed. 223 
From a manufacturing perspective, while it has been used to purify vaccines at commercial 224 
scales [60], ultracentrifugation has many limitations which have seen a reduction in usage for 225 
alternate methods such as filtration or chromatographic separation [61]. The reasons for this 226 
-- which may be applied directly to the future of exosome processing-- are largely due to the 227 
high level of skill and manual labor (gradient generation, sample balancing and pellet 228 
resuspension, all of which must be performed to high levels of precision), the time-intensive 229 
nature of the processes, the associated costs of reagents and equipment, and the 230 
observations of losses in potency of labile products. 231 
There are also significant limitations in interpreting process efficiency between different 232 
laboratories using different centrifuges. Indeed, exosome pelleting efficiency is dependent on 233 
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several parameters defined by the centrifuges themselves (e.g. k-factor, rotor type), meaning 234 
that processes are only readily transferable if identical equipment and protocols are used 235 
[62], [63]. When coupled with processing times that can extend to 72 hours for routine small 236 
scale operation, it is understandable that alternative process options have phased out 237 
ultracentrifugation in the viral/vaccine industries whenever possible. 238 
As with any form of biologics manufacturing, any reagents added during the process need to 239 
be removed from the final product and so additional considerations must be given for 240 
adequate clearance of substances used such as D2O or sucrose cushions. This leads to a 241 
requirement for additional pelleting steps, which increases operating costs, purification times 242 
and product losses due to process inefficiencies and aggregation [64], not to mention losses 243 
in biological activity [65]. To address manufacturing and regulatory uncertainty here, further 244 
advancements are needed. 245 
Non-specific precipitation, typically using polyethylene glycol (PEG)-based solutions, is an 246 
alternative method to sediment exosomes without the need for expensive ultracentrifuges. 247 
This method can sediment exosomes at lower centrifugal forces (around 20,000g), which can 248 
then be loaded into size-exclusion columns, though currently these columns are only 249 
commercially available as manually operated kits. However, these technologies may not be 250 
appropriate for larger scales. By way of illustration, the large pore sizes of the resins used will 251 
likely present challenges related to pressure limitations and compression at larger scales. 252 
Moreover, the added need to remove PEG from the end product, especially for injectables 253 
[42], may lead to a need for further processing and therefore, ultimately, product losses. One 254 
study showed that it was possible to make columns rather than rely on kits, and as similar 255 
levels of purification are achieved, the convenience of the kits far surpassed that of the 256 
columns [66]. 257 
Another concern with these sedimentation processes is the co-isolation of non-exosomal 258 
vesicles which can overlap in characteristics, must be identified and be sufficiently depleted 259 
in a therapeutic, so as to minimize safety risks to patients. Critically, one may also wish to 260 
enrich an exosome sub-population to increase the efficacy of a therapeutic which, with 261 




Recently, there has been an increase in the use of tangential-flow filtration to concentrate 264 
exosomes from cell-culture media based on their size [42], [67]–[69] . This process is more 265 
promising than the sedimentation methods listed above, due to tight and reproducible size 266 
distributions and the ease with which processes can be scaled and can facilitate product 267 
washes and buffer exchanges [52]. This makes tangential flow filtration extremely attractive 268 
as a primary recovery method. Moreover hollow fiber ultrafiltration coupled with 269 
microfiltration is a relatively gentle process that retains structural and functional integrity of 270 
exosomes while enabling the removal of large particles and cell-culture derived proteins [61]. 271 
However, there are some issues, as ultrafilters are expensive and the co-isolation of material 272 
such as serum proteins and DNA from cell culture continues to be problematic. Excessive 273 
fouling leading to elevated pressure in the system, and consequent associated shear forces, 274 
could also be detrimental to the final preparation and must be carefully monitored. 275 
All of the above downstream processing techniques are based on physical parameters and 276 
none have a way of completely discriminating exosomes beyond either size or density. This 277 
often leads to co-isolation of non-exosomal vesicles or organelles with overlapping physical 278 
characteristics, resulting in insufficiently pure exosome preparations. This was revealed when 279 
comparing density gradient and standard ultracentrifugation to an immuno-affinity capture 280 
method, as the latter increased exosome associated proteins by at least 2-fold over the 281 
ultracentrifugation options [70]. This can become particularly troublesome if large scale 282 
culture systems that lead to higher rates of cell death are employed in the future. A remedy 283 
to this potential burden would be the development of scalable processes which use methods 284 
of purification orthogonal to the current physical methods, i.e. which use the biochemical and 285 
biophysical characteristics of exosomes to discriminate from impurities via more precise 286 
processes. This need for reproducible and standardized platform technologies in the industry 287 
become apparent when literature searches for exosome purification yield varied and almost 288 
conflicting results with regards to which protocol is the most promising. Taking 289 
ultracentrifugation as an example, huge differences in efficiency of exosome recovery are 290 
reported across research groups [70]–[72] when compared to commercial kits and affinity-291 
base purification methods. In one such study, lab scale commercial kits processing human 292 
serum samples up to a volume of 5 mL isolated an 80-300 fold higher yield of exosomes than 293 
ultracentrifugation [51].  294 
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Of the reported methodologies for exosome purification, immuno-affinity methods are 295 
perhaps the most promising but least reported to date in the literature [43]. The method 296 
often cited is based on antibody-conjugated magnetic beads, which can be used to pull out 297 
exosome populations from crude material. A study comparing exosome recovery from human 298 
colon cancer cell line LIM1863 [70] revealed that exosomes captured via immuno-affinity 299 
were superior in terms of expression levels of known exosomal markers, compared with 300 
ultracentrifugation and differential centrifugation. Moreover, the vesicles were much more 301 
homogeneous (40-60 nm diameter) compared with those from ultracentrifugation (40-100 302 
nm) and differential centrifugation (50-100 nm). Moreover, immuno-affinity isolation enabled 303 
the identification of novel molecules, ESCRT-III component VPS32C/CHMP4C, and the SNARE 304 
synaptobrevin 2 (VAMP2), in exosomes for the first time [70]. This shows powerful potential 305 
in terms of product characterization and isolation. 306 
However, there are limitations when using beads. In the current format, scaling up becomes 307 
increasingly burdensome because mixing, mass transfer and removal of beads via magnetic 308 
separation is achieved with limited efficiency at the larger scales and also requires specialist 309 
equipment [73]. However, the use of these beads at laboratory scale suggest that they could 310 
have potential in large scale processing if the issues surrounding introduction of process 311 
impurities are successfully overcome.  312 
Realistically, the use of affinity methods is likely to be more economical and simpler to 313 
facilitate if antibodies are immobilized onto stationary phases, because with a stationary 314 
phase there is less opportunity for particulate impurities typically seen with beads. As such, 315 
further development of chromatographic steps which facilitate the specific capture of 316 
exosomes (or their subtypes) may likely be important. 317 
Another chromatographic method shown to be effective in separating exosomes from other 318 
process impurities based on their characteristic negative charge is ion-exchange 319 
chromatography. A recent study demonstrated the applicability of chromatographic 320 
purification by use of a quaternary amine (QA) anion exchange column (AEx column) against 321 
sucrose density gradient separation of amniotic fluid derived exosomes [74]. The results 322 
indicated that the quality of the exosomes was superior from anion exchange purification 323 
12 
 
over the more classical ultracentrifugation technique, in terms of soluble impurity removal 324 
and the separation of CD marker positive and negative exosomes [74].    325 
However, optimization of process conditions on a case by case basis is necessary as ion-326 
exchange chromatography may still co-elute host cell DNA and albumin if improperly 327 
implemented, and likely masked by the broad elution peaks of heterogeneous exosomes.  328 
A potentially beneficial advancement for chromatography would be to shift from traditional 329 
packed bed systems, which may not be appropriate for such particulate heavy feeds, to 330 
membrane or monolithic technologies with more open-pore structures that can 331 
accommodate exosome material while retaining separation power and increasing 332 
throughput. Increased throughput may be possible because higher flow rates can be used; 333 
this approach has already been adopted in the virus industry [75]. 334 
Currently used methods for purifying exosomes ideally need to be replaced with advanced 335 
platforms (Figure 4) and an ideal process for exosome purification should include a sequence 336 
of steps that comprises filtration-based recovery followed by chromatography-based 337 
purification; filtration-based recovery and concentration will deliver a product of defined size 338 
distribution and reduce the vast quantities of conditioned medium into a lower volume that 339 
is easier to process. Tangential flow filtration is a good candidate and concentrated MSC-340 
secreted exosomes up to 125-fold [30]. Further evidence for this shift in technologies is 341 
supported by a study where ultrafiltration and liquid chromatography (UF-LC) steps (in this 342 
case size exclusion chromatography using Sephacryl columns) were tested against differential 343 
ultracentrifugation [69]. The results showed significantly higher yields from the UF-LC method 344 
relative to differential ultracentrifugation without compromising the proteomic identity of 345 
EVs, while also showing that the biophysical properties were preserved. The authors also 346 
observed an improved bio-distribution of the EVs when injected into mice: fewer EVs 347 
accumulated in the lungs, likely due to the reduction of aggregation and damage to the 348 
exosomes during the UF-LC steps compared to ultracentrifugation[69]. 349 
Ideally, sequential filtration followed by affinity-based chromatography that targets EV-350 
specific surface proteins (e.g. CD81) may offer the best chance of success in clinical 351 
development; the chromatographic steps should deplete non-EV DNA and culture medium-352 
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derived proteins, and finally via the buffer exchange steps, allow washing and concentration 353 
of the product prior to formulation and secondary manufacture.   354 
The Analytics Challenge 355 
Without doubt, advances in upstream cell culture and downstream processing will advance 356 
exosomes towards routine manufacture. However, equally critical, and underpinning these 357 
advances, is the capacity to measure and characterize the exosome product better than 358 
currently achieved. It will be easier to address the process development and scale up of 359 
exosome product if the process is guided by a robust, regulatory accepted definition of what 360 
it is. The exosome community has already taken significant steps to provide a broad definition 361 
for exosomes and provide criteria for their identification. The International Society of 362 
Extracellular Vesicles (ISEV) has established a set of criteria for proteomic identification of 363 
exosomes with a minimal list of requirements [76], namely, exosomes should i) possess 364 
transmembrane proteins to provide evidence of a membrane (e.g. tetraspanins such as CD63, 365 
CD81 and CD9) [65], [77]; ii) possess cytosolic proteins to provide evidence of membrane or 366 
receptor binding capacity (e.g. TSG101, Rab proteins or annexins); iii) be free of protein 367 
impurities from intracellular compartments not associated with the plasma membranes or 368 
endosomes (e.g. endoplasmic reticulum, Golgi, mitochondria, nucleus); and iv) be free of co-369 
isolating extracellular proteins such cytokines and serum components.  370 
These, in combination with physical observations via electron microscopy and particle size 371 
distribution analysis, create a useful baseline. However, ultimately more detailed 372 
characterization must be undertaken to describe exosomes in terms of functional capacity by 373 
mechanistically defining the action of key nucleic acid and protein signals on target cells, and 374 
by understanding exosome heterogeneity. In addition, if possible, mapping exosome sub-375 
populations to define those harboring higher potency and/or defining unique components 376 
not present in other exosomes would be ideal. For example, a larger exosome may contain 377 
larger quantities of certain RNAs or proteins, or a smaller exosome may have a higher density 378 
of surface markers). Furthermore, assays need to be developed that detect exosomes with 379 
higher reliability and accuracy than at present. Examples of such steps have already been seen 380 
in the literature, for example using flow-cytometry, which can enable detection and semi-381 
quantitative analysis of specific markers [78], as well as microfluidic tools allowing rapid 382 
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sensing of exosomes using immunomagnetic capture targeting exosome markers such as 383 
CD63 [58]. This microfluidic approach even offers potential for development of in-line 384 
measurement technologies that can monitor exosome production during cell culture as a 385 
label-free surrogate measurement of the cells, and using exosome identity as a surrogate for 386 
cell identity and state. It might even be possible to isolate exosomes themselves using label-387 
free tools. For example, microfluidic devices have been developed that utilize transmission 388 
surface plasmon resonance [59] or acoustic waves [60] to isolate exosomes from other 389 
vesicles and cells. While these tools may not fulfill the requirement of a large scale purification 390 
platform, they might offer potential as label-free methods to isolate exosomes that can be 391 
subsequently characterized, (e.g. via arrays of antibodies for on-chip profiling of exosome 392 
surface proteins) [59]. 393 
Finally, in vitro potency assays need to truly predict outcomes in vivo, which in turn will feed 394 
back to evolving product specifications to enable development of exosomes as potential 395 
therapeutic agents.  396 
Viral Co-Isolation: A New Challenge on the Horizon? 397 
In terms of product safety, as a therapy which is derived from mammalian cells, there also is 398 
the risk of co-isolating endogenous viruses. Naturally, if the live cells are being used as a 399 
therapy in their own right and the exosomal product is a secondary product, the screening of 400 
adventitious agents such as viruses would be a pre-requisite and would lower risks of high 401 
titers entering the final product. Conversely, there is a risk that what is passably low, 402 
unobservable or unscreened in a cell, could be highly concentrated by downstream 403 
processing steps, many of which would be similar to those used for viral vaccine production 404 
(filtration, ultracentrifugation, precipitation/size exclusion, and even chromatographic 405 
technology if less-specific methods are used), due to the similarities in size and physical 406 
properties between viruses and exosomes. Furthermore, if, for example, dedicated cell lines 407 
for the production of exosomes for drug delivery or gene editing are created, mimicking 408 
recombinant protein and antibody production systems, one may find proof of viral removal is 409 
absolutely necessary. At this point, one must scrutinize the current technologies available and 410 
find methods where an exosome may be separated from any viruses which may be present.  411 
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Issues surrounding this are fairly apparent as exosomal and viral identity are highly similar: 412 
the size ranges often overlap (thereby making viral filtration an unamenable option) and, as 413 
both entities essentially consist of functional genetic material and surface proteins, chemical 414 
inactivation could damage the exosome as much as the virus in terms of disruption to 415 
functional surface proteins [79]. A common method of inactivation is that of exposure to low 416 
pH (3), typically during a chromatographic step: however, this method risks damaging 417 
exosomal surface proteins, or, if not strongly bound to the column, eluting the product 418 
altogether. Similarly, other techniques such as ultraviolet (UV) inactivation, which aim to 419 
disrupt the nucleic acid sequences for viral attenuation, could also irreparably damage the 420 
exosome product. This poses a further challenge on the analytical spectrum because even if 421 
exosomes could be shown to be up-taken in using in vitro quality control assays (due to the 422 
lack of damage to surface proteins), any damage to the internal genetic material may cause 423 
them to perform with limited or null activity biologically which reinforces the need for suitable 424 
potency assays.  425 
More complex procedures such as heat treatment options including pasteurisation, dry heat 426 
and vapor heat, can also be used for viral inactivation; however, while a single protein could 427 
be protected sufficiently by a protein stabilizer (presumably also slightly protecting the virus) 428 
due to the size and make-up of exosomes, finding a way to maximize exosomal function while 429 
sufficiently removing virus might also be difficult to achieve, especially when taking into 430 
account the relatively complex optimization and implementation of these processes 431 
compared to UV or pH inactivation [80]. 432 
 433 
Concluding Remarks 434 
Exosomes are promising new candidate therapies and the recent explosion in research into 435 
exosome biology and function has caused global excitement. With several prominent pre-436 
clinical studies showing potent effects of exosomes, and some early clinical data are 437 
emerging, it is timely to address the bioprocessing challenges that underpin manufacture of 438 
exosomes and other EVs. While phenomenal progress has been made in understanding the 439 
biological properties of exosome cargo, research must also focus on challenges related to 440 
achieving regulatory approval and potential translational into the clinical setting.  441 
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The most promising manufacturing approach to make in the first instance may be adoption 442 
of an advanced purification platform based on a two-step filtration-chromatography 443 
approach that can enable scalable and pure exosome products to be created. There are still 444 
many unanswered questions and hurdles to overcome, (see Outstanding Questions and Box 445 
1), in order to deliver exosomes as a new putative therapeutic tools for healthcare. These 446 
challenges will come in many forms: from scheduling and batch reproducibility, to process 447 
robustness and economic feasibility, along with thoroughly defining meaningful critical 448 
quality attributes for the product itself. It is vital that these issues are investigated fully in 449 
parallel with clinical validation studies in order to contemplate delivering exosomes to the 450 
clinic and to the patients who might benefit.  451 
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Figure List 452 
Figure 1: Exosome biogenesis. Exosome biogenesis (left) begins when multi-vesicular bodies 453 
(MVBs) (1) bud inwards to form intraluminal vesicles (ILVs) that are loaded with genetic 454 
material and proteins (2). Next, MVBs fuse either with lysosomes (3A) which results in 455 
proteolytic degradation of exosomal contents, or with the plasma membrane (3B), resulting 456 
in the release of ILVs, now referred to as exosomes, into the extracellular environment. Non-457 
exosomal vesicles bud directly from the cell membrane (4). Exosomes are typically in the size 458 
range of 20-150nm and their structure (right) is complex. Tetraspanins (e.g. CD81, CD63, CD9) 459 
and other transmembrane proteins such as adhesion receptors are present at the surface, 460 
while internally, the cargo comprises an array of proteins (cytosolic, cytoskeletal, growth 461 
factors) and miRNAs that convey specific functional cues. 462 
Figure 2: Exosomes and stem cell transplantation. Diagrammatic representation of exosome 463 
function after in vivo stem cell transplantation. Implanted stem cells synthesize exosomes 464 
that convey functional characteristics of parental cells (a). Exosomes are then released by 465 
stem cells into the surrounding environment (b) and induce functional responses in adjacent 466 
resident tissue cells (c) that can modify the behavior of target cells, even resulting in sustained 467 
regenerative responses (d) after the stem cell has perished or exited the injury site.  468 
Figure 3: Upstream processing of stem cells. Schematic showing the current laboratory scale 469 
methods used for upstream processing of stem cells (top). Cells are retrieved from the patient 470 
or from a working cell bank (WCB) and expanded predominantly using a T-flask platform. This 471 
leads to a number of significant pitfalls associated with current technologies. Development of 472 
new upstream processing is necessary (bottom) in order to scale up the production of large 473 
quantities of cells from the WCB and therefore large quantities of exosome product that can 474 
be made in a closed bioreactor system and with greater process control. 475 
Figure 4: Downstream processing of stem cells. Diagrammatic representation of the current 476 
laboratory scale methods used for downstream processing of stem cell-derived exosomes 477 
(top). Crude conditioned media concentration is achieved using filtration and then 478 
ultracentrifugation methods are used to isolate exosomes on the basis of size and density. 479 
Future processing needs to be scalable and so tangential flow filtration (TFF), followed by 480 
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affinity capture and final polishing steps are most promising to deliver high purity exosome 481 
therapies (bottom).  482 
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Glossary terms 763 
Downstream processing The manufacturing steps after cell culture, that typically 764 
involve purification, washing, concentration and formulation 765 
of the product. 766 
Dynamic bioreactor systems Bioreactors that use a agitation to ensure adequate mixing and 767 
mass transfer when compared with static systems. 768 
Exosome An extracellular vesicle that is created in multi-vesicular bodies 769 
and then released from the cell into the extracellular 770 
environment via a process of exocytosis 771 
Extracellular vesicle Membrane-enclosed package of material that is generated via 772 
several distinct biologic pathways 773 
Flask bioreactors A modified form of cell culture flask with advanced functions, 774 
for example separation of the liquid and air phases or 775 
compartmentalisation to collect secreted product using 776 
membrane technology 777 
Hollow-fiber bioreactors A 3D bioreactor that uses parallel bundles of semi-permeable 778 
capillaries that allow transfer of nutrients and gases to the 779 
cells residing in the extra-capillary spaces 780 
Impellers A rotating blade or paddle in a bioreactor that agitates the 781 
culture medium to ensure even mixing and distribution of 782 
nutrients 783 
Mass transfer The net movement of mass from one place to another. 784 
Packed bed technologies Bioreactor technologies that use a tube filled with particles 785 
that act as a physical substrate for cell attachment and growth. 786 
They allow perfusion of culture media to distribute nutrients 787 
and oxygen bed 788 
Oxygen sparging Introducing oxygen bubbles into the bioreactor to dissolve 789 
oxygen in the culture medium 790 
Shear stress A force experienced by cells in a bioreactor due to the flow of 791 
culture medium parallel to their surface 792 
Tangential-flow filtration A method for separating and purifying biomolecules whereby 793 
the solution is passed tangentially across the filtration 794 
membrane rather than directly at it. 795 
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Transmission surface plasmon resonance A technique commonly used in microfluidic 796 
applications that can detect adsorption of biologic material to 797 
metal surfaces 798 
Box 1. Clinician’s Corner  799 
Exosomes are cell-secreted vesicles containing bioactive proteins and genetic material. Their 800 
specific cargo is reflective of the parent cell, and gives rise to their therapeutic effects. 801 
 Stem-cell derived exosomes have potential for use as drug candidates for a wide host 802 
of indications. However, to achieve potential as therapeutics scalable manufacturing 803 
processes are needed, both upstream and downstream.  804 
 Upstream processing needs to include scalable cell culture that can produce large 805 
quantities of secreted exosomes. Current bioreactor technology is designed for 806 
suspension-adapted cells that are used to make antibodies or recombinant proteins. 807 
They are typically not suitable for scalable expansion of adherent cells. 808 
 Downstream processing needs to transition from traditional ultracentrifugation 809 
methods to combinations of filtration and chromatographic-based methods that can 810 
achieve consistent and reproducible purification at scale. 811 
 Manufacturing science needs to be addressed early in the product development cycle 812 
so that exosomes can achieve status as routine therapies more quickly and cost-813 
effectively. 814 
 815 
